TP53 and neoplasm: Nuclear p65 and p53 co-localization was found in 42 (12.5%) of the studied patients and was associated with high tumor grade (52.4% in cases with co-localization vs 34.2% in cases without co-localization; p=0.030), negativity for ER (64.3% vs 21.7%; p=0.001), HER2 amplification (35.7% vs 17.3%; p=0.005), high proliferation (38.1% vs 24.0%; p=0.042) and relapse (38.1% vs 18.1%; p=0.003).